Recombinant proteins, polyclonal and monoclonal antibodies

submitted by: Randox
Randox Life Sciences develops and manufactures a wide range of products which includes high quality antibodies and conjugates targeting drugs of abuse, steroids, hormones and biochemical markers. Randox Life Sciences also offers customers our extensive list of human recombinant cytokines, chemokines, adhesion molecules and tumour markers. Our extensive range consists of more than 1000 products all manufactured at our state of the art, ISO 13485 accredited manufacturing plant in the United...

Antibody Detection and Viral Cures

submitted by: Johnny Pietersen
http://www.biogetica.com - This Video discusses how the presence of Anti-bodies is linked to Viruses. Antibodies are created by your body to fight a virus. These specific anti-bodies are tell tale signs of past or present viral infections or vaccinations. Blood tests do not actually detect the virus; instead they look for antibodies (the body's immune response) in the blood. The presence of life long anti-bodies is now used to label viruses as incurable. Once you've had a certain virus you...

Computational Lab - Prof. Cristian Coarfa (2009)

submitted by: ralanharris

An introduction to computational methods for analyzing ChIP-Seq data by Cristian Coarfa. This was presented as a lab within the Computer Aided Discovery Methods course offered within the Graduate Program at Baylor College of Medicine.

TGFß & Alzheimer's Disease

submitted by: alex01

R.A. Flavell (Yale University, New Haven, CT) discusses the role of Transforming Growth Factor ß (TGFß) in disease. In the central nervous system of a murine model of AD this cytokine appears to prevent macrophages from attacking ß-amyloid. Flavell visualizes that selective blockade of this TGFß
activity could lead to the destruction of plaques in patients with AD.

Drug Discovery for Alzheimer's Disease

submitted by: alex01

Gregory Rose from PharmExperts.com interviews J. Buccafusco (Medical College of Georgia, Augusta, GA) about his development of new anti-Altzheimer drugs, designed to act by multiple mechanisms to improve congnition. Desensitization of nicotinic receptors is one of the novel approaches proposed by Buccafusco. Three of his compounds are currently in advanced preclinical evaluation.